Translate Bio, Inc. Stock News

Telesis Bio (NASDAQ: TBIO ) stock is on the rise Friday as the synthetic biology company's shares experienced heavy trading this morning. Shares of TBIO stock are off to a strong start on Friday with

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its second quarter 2023

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, announced that Todd R. Nelson, Ph.D., CEO and Founder of

Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery

Highlighting application of the Molecular Biology Workstation to accelerating vaccine and biologics discovery Highlighting application of the Molecular Biology Workstation to accelerating vaccine and

Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics Applications Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics Applications

Telesis Bio (TBIO) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.45 per share a year ago.

SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its first quarter 2023

Telesis Bio, Inc. (NASDAQ:TBIO ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Jen Carroll - VP, IR Todd Nelson - President, CEO & Director Eric Esser - COO Conferenc

Telesis Bio (TBIO) delivered earnings and revenue surprises of 12.50% and 5.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Daniel Gibson, Ph.D., CTO and Co-founder to Present “Building Biology Overnight: Eliminating Synthesis Bottlenecks with Hands-free Automated Synthetic Biology Solutions” Daniel Gibson, Ph.D., CTO

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Showcasing Benchtop Automation for mRNA Synthesis beginning from Sequence or Plasmid DNA Showcasing Benchtop Automation for mRNA Synthesis beginning from Sequence or Plasmid DNA

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its fourth quarter and

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that Todd R. Nelson, PhD, the company's